NCT03979742

Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training

Terminated Phase 2 Last updated 28 February 2025

What this trial tests

Phase 2 trial testing Umbilical Cord Blood Mononuclear Cell in Spinal Cord Injuries in 6 participants. Terminated before completion.

Timeline

22 February 2022

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	StemCyte, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	22 February 2022
Primary completion	30 December 2024
Estimated completion	30 December 2024
Sites	2 locations across Taiwan

Drugs / interventions tested

• Umbilical Cord Blood Mononuclear Cell — full drug profile →
• Locomotor Training

Conditions studied

• Spinal Cord Injuries — all drugs for Spinal Cord Injuries →

Sponsor

StemCyte, Inc. — full company profile →

Who can join

Adults 18 to 60, any sex, with Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Umbilical cord blood mononuclear stem cells (UCBMSCs) transplant followed by the intensive locomotor training for up to 5±1 hours a day, 5±1 days a week, and for 3-6 months for treatment in patients with chronic, stable and complete spinal cord injury.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury.
   Khaing ZZ, Chen JY, Safarians G, Ezubeik S, et al · · 2023 · cited 26× · PMID 36835233 · DOI 10.3390/ijms24043824
2. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future.
   Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, et al · · 2023 · cited 26× · PMID 36779789 · DOI 10.1093/stcltm/szac086
3. Umbilical cord blood: The promise and the uncertainty.
   Kindwall-Keller TL, Ballen KK. · · 2020 · cited 26× · PMID 32619330 · DOI 10.1002/sctm.19-0288
4. Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury.
   Suzuki H, Imajo Y, Funaba M, Nishida N, et al · · 2021 · cited 22× · PMID 35185471 · DOI 10.3389/fncel.2021.794692
5. Current Concepts of Stem Cell Therapy for Chronic Spinal Cord Injury.
   Suzuki H, Sakai T. · · 2021 · cited 22× · PMID 34299053 · DOI 10.3390/ijms22147435
6. Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury.
   Szymoniuk M, Litak J, Sakwa L, Dryla A, et al · · 2022 · cited 20× · PMID 36611914 · DOI 10.3390/cells12010120
7. Conductive and injectable hyaluronic acid/gelatin/gold nanorod hydrogels for enhanced surgical translation and bioprinting.
   Kiyotake EA, Thomas EE, Homburg HB, Milton CK, et al · · 2022 · cited 18× · PMID 34390325 · DOI 10.1002/jbm.a.37294
8. Fresh Umbilical Cord Blood-A Source of Multipotent Stem Cells, Collection, Banking, Cryopreservation, and Ethical Concerns.
   Devi S, Bongale AM, Tefera MA, Dixit P, et al · · 2023 · cited 17× · PMID 37763198 · DOI 10.3390/life13091794